Results 11 to 20 of about 5,297,540 (313)

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.

Lung Cancer, 2023
OBJECTIVES Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been approved for EGFR-mutant non-small-cell lung cancer (NSCLC).
C. Lv, W. Fang, N. Wu, W. Jiao, Shidong Xu, Haitao Ma, Jia Wang, Rui Wang, C. Ji, Shaolei Li, Yu-zhao Wang, Shi Yan, F. Lu, Y. Pei, Yinan Liu, Yue Yang   +15 more
semanticscholar   +1 more source

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

Frontiers in Oncology, 2022
IntroductionNeoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer.
Mao Shang, Mao Shang, Yajing Chi, Jianbo Zhang, Jin Chang, Hui Yang, Sha Yin, Qiaorui Tan, Xiaochu Man, Huihui Li   +9 more
doaj   +1 more source

Total neoadjuvant therapy for rectal cancer: a guide for surgeons

Canadian journal of surgery. Journal canadien de chirurgie, 2023
Summary The modern management of rectal cancers continues to evolve. With the release of data from new landmark randomized controlled trials (RAPIDO, PRODIGE-23), total neoadjuvant therapy (TNT) has moved to the forefront of locally advanced rectal ...
Garrett Johnson, Jason Park, R. Helewa, B. Goldenberg, M. Nashed, E. Hyun   +5 more
semanticscholar   +1 more source

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Frontiers in Pharmacology, 2023
Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation ...
Yongbao Wei, Yongbao Wei, Ruochen Zhang, Ruochen Zhang, Dewen Zhong, Zhensheng Chen, Gen Chen, Minggen Yang, Le Lin, Le Lin, Tao Li, Tao Li, Liefu Ye, Liefu Ye, Lili Chen, Lili Chen, Qingguo Zhu, Qingguo Zhu   +17 more
doaj   +1 more source

Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer.

Cancer Cell, 2022
Standard cancer therapy targets tumor cells without considering possible damage on the tumor microenvironment that could impair therapy response. In rectal cancer patients we find that inflammatory cancer-associated fibroblasts (iCAFs) are associated ...
Adele M. Nicolas, M. Pesic, Esther Engel, Paul K Ziegler, M. Diefenhardt, Kilian B. Kennel, F. Buettner, Claire Conche, V. Petrocelli, Eiman Elwakeel, A. Weigert, A. Zinoveva, Maximilian Fleischmann, B. Häupl, Cem Karakütük, H. Bohnenberger, M. H. Mosa, L. Kaderali, J. Gaedcke, M. Ghadimi, F. Rödel, M. C. Arkan, T. Oellerich, C. Rödel, E. Fokas, F. Greten   +25 more
semanticscholar   +1 more source

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Frontiers in Oncology, 2022
Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated.
Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu   +5 more
doaj   +1 more source

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.

JAMA Oncology, 2021
Importance Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established.
E. Fokas, A. Schlenska-Lange, B. Polat, G. Klautke, G. Grabenbauer, R. Fietkau, T. Kuhnt, L. Staib, T. Brunner, A. Grosu, S. Kirste, L. Jacobasch, M. Allgäuer, M. Flentje, Christoph‐Thomas Germer, R. Grützmann, G. Hildebrandt, M. Schwarzbach, W. Bechstein, H. Sülberg, T. Friede, J. Gaedcke, M. Ghadimi, R. Hofheinz, C. Rödel   +24 more
semanticscholar   +1 more source

Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics

Signal Transduction and Targeted Therapy, 2023
Dear Editor , Preoperative neoadjuvant therapy combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). However, more than half of patients having a partial response to neoadjuvant therapy,
Yushang Yang, Yanguo Li, Hao-Peng Yu, Z. Ding, Longqi Chen, Xiaoxi Zeng, Shunmin He, Q. Liao, Yi Zhao, Yong Yuan   +9 more
semanticscholar   +1 more source

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Frontiers in Immunology, 2022
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable ...
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu   +11 more
doaj   +1 more source

Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.

European Journal of Cancer, 2021
INTRODUCTION Neoadjuvant therapy may improve survival compared with upfront surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality evidence is lacking.
J. V. van Dam, Q. Janssen, M. Besselink, M. Homs, H. V. van Santvoort, G. van Tienhoven, R. D. de Wilde, J. Wilmink, C. V. van Eijck, B. Groot Koerkamp   +9 more
semanticscholar   +1 more source